H.C. Wainwright analyst Andrew Fein assumed coverage of MetaVia (MTVA) with a Buy rating and $12 price target The firm says Metavia offers a “compelling opportunity” in the metabolic disease space based on its two “differentiated” pipeline programs.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTVA:
- MetaVia Inc. Reports Q2 2025 Financial Results and Strategic Progress
- Optimistic Buy Rating for MetaVia Driven by Promising Obesity Drug Developments and Strategic Collaborations
- MetaVia Highlights Clinical Trials and Future Plans
- MetaVia Extends Phase 1 Trial for Obesity Drug
- MetaVia extends Phase 1 clinical trial of DA-1726